Deep Genomics vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deep Genomics uses AI to discover and design RNA-based therapies for genetic diseases; its AI Workbench platform decodes RNA biology at scale; raised over $180M in funding including a $40M Series C extension in 2022;
About
Deep Genomics is a biopharmaceutical company founded in 2015 by Brendan Frey and headquartered in Toronto, Ontario, Canada. The company applies artificial intelligence to the challenge of RNA biology — developing a proprietary AI Workbench platform that can predict how genetic variants affect RNA splicing, processing, and gene expression. This computational capability allows Deep Genomics to identify disease-causing mutations that alter RNA function and to design antisense oligonucleotide (ASO) and other RNA-based therapies that correct those molecular defects — a process that traditionally requires years of manual biological experimentation.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.